Log in to your Inderes Free account to see all free content on this page.
Camurus
567
SEK
+0.62 %
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
9 following
+0.62%
-1.05%
-10.07%
-1.39%
+5.39%
+8.83%
+296.5%
+568.63%
+838.34%
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Read moreMarket cap
33.38B SEK
Turnover
18.43M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.2.
2025
Annual report '24
15.5.
2025
Interim report Q1'25
27.5.
2025
General meeting '24
ShowingAll content types
Camurus AB: Camurus to present at Jefferies London Healtcare Conference
Camurus, Audiocast with teleconference, Q3'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio